ADMA Biologics (ADMA) to Release Quarterly Earnings on Thursday

ADMA Biologics (NASDAQ:ADMA - Get Free Report) is scheduled to announce its earnings results after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of $0.13 per share for the quarter. ADMA Biologics has set its FY 2024 guidance at EPS and its FY 2025 guidance at EPS.Persons interested in registering for the company's earnings conference call can do so using this link.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.05. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The firm had revenue of $107.20 million during the quarter, compared to the consensus estimate of $86.44 million. During the same quarter last year, the firm earned ($0.02) EPS. The firm's revenue for the quarter was up 78.4% on a year-over-year basis. On average, analysts expect ADMA Biologics to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

ADMA Biologics Stock Down 3.8 %

ADMA traded down $0.65 during trading hours on Thursday, hitting $16.31. 2,900,922 shares of the company's stock were exchanged, compared to its average volume of 3,592,765. The firm has a market cap of $3.78 billion, a P/E ratio of -848.00 and a beta of 0.62. ADMA Biologics has a 12-month low of $3.23 and a 12-month high of $21.13. The company has a current ratio of 6.87, a quick ratio of 2.80 and a debt-to-equity ratio of 0.74. The firm has a 50 day moving average of $17.86 and a 200 day moving average of $13.25.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on ADMA. HC Wainwright reiterated a "buy" rating and issued a $18.00 target price on shares of ADMA Biologics in a report on Monday, October 14th. Cantor Fitzgerald restated an "overweight" rating and set a $20.00 target price on shares of ADMA Biologics in a research note on Friday, September 20th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, ADMA Biologics currently has an average rating of "Buy" and an average price target of $15.50.

Insider Buying and Selling at ADMA Biologics

In other news, Director Young Kwon sold 60,000 shares of the company's stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the completion of the transaction, the director now directly owns 241,441 shares of the company's stock, valued at approximately $4,408,712.66. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, Director Young Kwon sold 60,000 shares of the stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total value of $1,095,600.00. Following the transaction, the director now directly owns 241,441 shares of the company's stock, valued at $4,408,712.66. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Jerrold B. Grossman sold 136,861 shares of the firm's stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $17.27, for a total value of $2,363,589.47. Following the transaction, the director now directly owns 467,305 shares in the company, valued at approximately $8,070,357.35. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 466,900 shares of company stock worth $8,224,121 over the last ninety days. Corporate insiders own 3.70% of the company's stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.